{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:25:00Z","timestamp":1767165900339,"version":"build-2238731810"},"reference-count":48,"publisher":"Wiley","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FW Medical Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Research and Practice"],"published-print":{"date-parts":[[2023,12,16]]},"abstract":"<jats:p>\n                    Background. Irritable bowel syndrome (IBS) is a common chronic gut-brain interaction disorder with limited effective treatment options. Intestinal adsorbents have a high adsorption capacity for gut irritants and may provide nonpharmacological alternatives. Objectives. This post marketing study is aimed at providing up-to-date evidence to support the safety and efficacy in normal use of an established medical device for IBS treatment. Methods. In this open-label, observational study, adults with IBS with predominant diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M), according to Rome IV criteria, received 4 weeks of treatment with the enteroadsorbent Silicol\u00aegel, a CE-certified, licenced, medical device containing colloidal silicic acid. Eligible participants were assessed at baseline (visit 1; in-clinic) and after 1 (visit 2; telephone), 2 (visit 3; telephone), and 4 (visit 4; in-clinic) weeks of treatment. The primary endpoint was the proportion of participants with an overall reduction in the IBS severity scoring system\n                    <jats:inline-formula>\n                      <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mfenced open=\"(\" close=\")\">\n                          <a:mrow>\n                            <a:mtext>IBS<\/a:mtext>\n                            <a:mtext>\u2009<\/a:mtext>\n                            <a:mtext>SSS<\/a:mtext>\n                          <\/a:mrow>\n                        <\/a:mfenced>\n                        <a:mo>&gt;<\/a:mo>\n                        <a:mn>50<\/a:mn>\n                      <\/a:math>\n                    <\/jats:inline-formula>\n                    , representing clinically meaningful improvement. Key secondary endpoints were a reduction in common IBS symptoms and improved quality of life (QoL). Results. Among the 67 treated participants (IBS-D: 37; IBS-M: 30), 65 completed the study. At visit 4, 83.6% (56\/67) of participants achieved a reduction in IBS\n                    <jats:inline-formula>\n                      <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <e:mtext>SSS<\/e:mtext>\n                        <e:mo>&gt;<\/e:mo>\n                        <e:mn>50<\/e:mn>\n                      <\/e:math>\n                    <\/jats:inline-formula>\n                    . The mean (standard deviation [SD]) IBS SSS was 323.4 (55.7) at visit 1 and 160.3 (90.3) at visit 4 (overall change: -163.1 (101.7); 95% confidence interval [CI] 138.3, 187.9,\n                    <jats:inline-formula>\n                      <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <g:mi>p<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.001<\/g:mn>\n                      <\/g:math>\n                    <\/jats:inline-formula>\n                    ). Compared with visit 1, significant reductions in the severity of all key IBS symptoms and overall improvement in QoL were observed at visit 4 (\n                    <jats:inline-formula>\n                      <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <i:mi>p<\/i:mi>\n                        <i:mo>&lt;<\/i:mo>\n                        <i:mn>0.001<\/i:mn>\n                      <\/i:math>\n                    <\/jats:inline-formula>\n                    ), with improvements observed from visits 1 and 2. Conclusions. In this open-label study of participants with IBS-D and IBS-M, Silicol\u00aegel provided clinically significant improvement in IBS symptoms, demonstrating that enteroadsorbents may be clinically beneficial in this population.\n                  <\/jats:p>","DOI":"10.1155\/2023\/3432763","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:35:05Z","timestamp":1702744505000},"page":"1-14","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of the Enteroadsorbent Silicol\u00aegel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study"],"prefix":"10.1155","volume":"2023","author":[{"given":"Gordon","family":"Crawford","sequence":"first","affiliation":[{"name":"CPS Research, McCafferty House, 99 Firhill Road, Glasgow, G20 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Taylor","sequence":"additional","affiliation":[{"name":"CPS Research, McCafferty House, 99 Firhill Road, Glasgow, G20 7BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, G1 1XH, UK"},{"name":"NHS, Greater Glasgow and Clyde, 1055 Great Western Road, Glasgow, G12 0XH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6959-2653","authenticated-orcid":true,"given":"Chris G.","family":"Hatton","sequence":"additional","affiliation":[{"name":"FW Medical Ltd, West of Scotland Science Park, Kelvin Campus, Block 6, Glasgow, G20 0SP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324598"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.014"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820977402"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15325"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2500-07.2008"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.336"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-11-94"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-7-79"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13074"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12982"},{"key":"12","article-title":"Global Impact Report","author":"IBS","year":"2018"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0262-x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i26.8103"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40365.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305989"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201904_17580"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16939"},{"key":"19","article-title":"Gastrointestinal Society 2016 Survey Results: Irritable Bowel Syndrome (IBS)","author":"Canadian Society of Intestinal Research"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.14"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04895.x"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04818.x"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327293"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360170207027"},{"issue":"1","key":"25","first-page":"63","article-title":"Emergency medicine: activated charcoal-the first-line agent in cases of overdose","volume":"151","author":"D. A. Guss","year":"1989","journal-title":"The Western Journal of Medicine"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/750750"},{"key":"27","article-title":"Surface acting drugs","volume-title":"The Pharmacological Basis of Therapeutics","author":"E. A. Swinyard","year":"1980","edition":"6th"},{"issue":"31","key":"28","first-page":"1604","article-title":"Akute diarroe: diagnostik und therapie","volume":"122","author":"G. Kachel","year":"1982","journal-title":"Deutsche Apotheker Zeitung"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1185\/03007998209109772"},{"key":"30","first-page":"6185","article-title":"Kolloidales siliciumdioxid bei colitis ulcerosa und morbus Crohn - eine therapeutische alternative zur herk\u00f6mmlichen behandlung","volume":"32","author":"S. Wagner","year":"1982","journal-title":"Die Therapiewoche"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42176-z"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000287"},{"key":"33","article-title":"FW Medical Ltd. SilicolGel"},{"key":"34","article-title":"Medical Devices Regulation EU2017\\745 (Medical Devices), Article 86","author":"European Parliament"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.142318000.x"},{"key":"36","article-title":"Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome 25 September 2014 EMA\/CPMP\/EWP\/785\/97 Rev. 1 European Medicines Agency, Committee for Medicinal Products for Human use"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.13"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.201"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818798791"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.3310\/hta23170"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-208"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0195-4"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0084-x"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17179"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00273.x"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15572580"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318160"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2014.20.2.163"}],"updated-by":[{"DOI":"10.1155\/grp\/9856930","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000}}],"container-title":["Gastroenterology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/grp\/2023\/3432763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/grp\/2023\/3432763.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/grp\/2023\/3432763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:35:14Z","timestamp":1702744514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/grp\/2023\/3432763\/"}},"subtitle":[],"editor":[{"given":"Naohisa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":48,"alternative-id":["3432763","3432763"],"URL":"https:\/\/doi.org\/10.1155\/2023\/3432763","relation":{},"ISSN":["1687-630X","1687-6121"],"issn-type":[{"value":"1687-630X","type":"electronic"},{"value":"1687-6121","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,16]]}}}